MUC1 and interstitial lung disease: This study delves into the exploration of Krebs von den Lungen-6 (KL-6) as a potential biomarker to assess the severity and progression of interstitial lung diseases (ILDs), with a particular focus on progressive pulmonary fibrosis (PPF) compared to non-progressive (nPPF).